Clinical trial
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
NCT00252811 · AstraZeneca, Industry · Withdrawn
Key facts
| NCT number | NCT00252811 |
|---|---|
| Title | A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer |
| Official title | A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery |
| Lead sponsor | AstraZeneca, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 60 |
| Start date | Feb 1, 2004 |
| First posted | Nov 15, 2005 |
| Last update posted | Jan 28, 2011 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: